GRI Bio Inc
NASDAQ:GRI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Times Neighborhood Holdings Ltd
HKEX:9928
|
CN |
|
Il Sole 24 Ore SpA
LSE:0RUI
|
IT |
|
S
|
Shanghai Baosight Software Co Ltd
SSE:900926
|
CN |
GRI Bio Inc
EPS (Diluted)
GRI Bio Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GRI Bio Inc
NASDAQ:GRI
|
EPS (Diluted)
-$59
|
CAGR 3-Years
96%
|
CAGR 5-Years
83%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$8
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$3
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$7
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$22
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
GRI Bio Inc
Glance View
GRI Bio Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in La Jolla, California and currently employs 2 full-time employees. The company went IPO on 2021-02-10. GRI Bio, Inc. is a clinical-stage biotechnology company. The firm is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The firm's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company’s second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need.
See Also
What is GRI Bio Inc's EPS (Diluted)?
EPS (Diluted)
-59.6
USD
Based on the financial report for Dec 31, 2025, GRI Bio Inc's EPS (Diluted) amounts to -59.6 USD.
What is GRI Bio Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
83%
Over the last year, the EPS (Diluted) growth was 96%. The average annual EPS (Diluted) growth rates for GRI Bio Inc have been 96% over the past three years , 83% over the past five years .
